Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Lubar & Co., Inc | HNRG Hallador Energy Co | 13D/A | 11.49% | Feb 23, 2024 | 2y |
| Shufu Li | PSNY Polestar Automotive Holding UK PLC | 13D/A | 88.3% | Feb 23, 2024 | 2y |
| Monte M. Brem | STEP StepStone Group Inc. | 13D/A | 48.3% | Feb 23, 2024 | 2y |
| Benjamin G. Wolff | PDYN Palladyne AI Corp. | 13D/A | 6.1% | Feb 23, 2024 | 2y |
| Ephraim G Fields | NURO NeuroMetrix, Inc. Common Stock | 13D | 9.3% | Feb 23, 2024 | 2y |
| HGGC Fund IV GP, Ltd. | UPLD Upland Software, Inc. | 13D/A | 20.19% | Feb 23, 2024 | 2y |
| Krensavage Asset Management, LLC | ENTA Enanta Pharmaceuticals Inc | 13G | 5.1% | Feb 22, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | HARP Harpoon Therapeutics, Inc. Common Stock | 13D | 4.03% | Feb 22, 2024 | 2y |
| Klaus Umek | CRTO Criteo S.A. | 13D | 5.6% | Feb 22, 2024 | 2y |
| Lytton, Laurence W. | AZTR Azitra, Inc. | 13G | 5.8% | Feb 14, 2024 | 2y |
| Phillip Frost, M.D. | BCDA BioCardia, Inc. | 13D/A | 6.1% | Feb 14, 2024 | 2y |
| INGALLS & SNYDER LLC | HYFT MindWalk Holdings Corp. | 13G | 5.01% | Feb 13, 2024 | 2y |
| Union Square Park Capital Management, LLC | REED Reed's, Inc. | 13D/A | 17.98% | Feb 8, 2024 | 2y |
| John Michael DiMaio | MDAI Spectral AI, Inc. | 13D/A | 15.3% | Feb 7, 2024 | 2y |
| Undavia Nilesh | EAF Graftech International Ltd | 13D/A | 5.74% | Feb 2, 2024 | 2y |
| Walleye Capital LLC | AQUC Aquaron Acquisition Corp. | 13G | 7.82% | Dec 31, 2023 | 2y |
| AMERIPRISE FINANCIAL INC | PIII P3 Health Partners Inc. | 13G/A | 4.72% | Dec 31, 2023 | 2y |
| Walleye Capital LLC | ACU Acme United Corp | 13G/A | 0% | Dec 31, 2023 | 2y |
| Alpha Intelligence Enterprises Ltd | APLM Apollomics Inc. | 13G | 8.66% | Dec 31, 2023 | 2y |
| Patient Capital Management, LLC | PGEN Precigen, Inc. | 13G/A | 6.42% | Dec 29, 2023 | 2y |
| Bitfury Top HoldCo B.V. | CIFR Cipher Digital Inc. | 13D/A | 46.2% | Feb 26, 2024 | 2y |
| CoyCo GP, L.L.C. | RCM R1 RCM Inc. Common Stock | 13D/A | 32.4% | Feb 26, 2024 | 2y |
| COLUMN GROUP L P | NGM NGM Biopharmaceuticals, Inc. Common Stock | 13D/A | 26.7% | Feb 25, 2024 | 2y |
| Findell Capital Partners LP | OPRT Oportun Financial Corp | 13D/A | 6.5% | Feb 23, 2024 | 2y |
| Yoda PLC | CCEC Capital Clean Energy Carriers Corp. | 13D/A | 25.7% | Feb 23, 2024 | 2y |
| Indaba Capital Management, L.P. | ONTF ON24 INC. | 13D/A | 10.2% | Feb 22, 2024 | 2y |
| Starboard Value LP | FTRE Fortrea Holdings Inc. | 13D/A | 6.9% | Feb 22, 2024 | 2y |
| Cano Health, Inc. | MSPR MSP Recovery, Inc. | 13D/A | 32% | Feb 22, 2024 | 2y |
| Antofagasta plc | BVN Buenaventura Mining Co Inc | 13D/A | 18.9% | Feb 22, 2024 | 2y |
| Christopher Scott Ginieczki, as Personal Representative of the Estate of Geoffrey S. M. Hedrick | IA Innovative Solutions & Support Inc | 13D/A | 6.09% | Feb 22, 2024 | 2y |
| Edward S. Lampert | SRG Seritage Growth Properties | 13D/A | 24.1% | Feb 22, 2024 | 2y |
| GLOBAL VALUE INVESTMENT CORP. | RMCF Rocky Mountain Chocolate Factory, Inc. | 13D/A | 17.93% | Feb 22, 2024 | 2y |
| Michael P. Nieri | UHG United Homes Group, Inc. | 13D/A | 76.98% | Feb 22, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | LRMR Larimar Therapeutics, Inc. | 13G | 9.5% | Feb 16, 2024 | 2y |
| Venrock Healthcare Capital Partners III, L.P. | ENGN enGene Therapeutics Inc. | 13G | 5.9% | Feb 16, 2024 | 2y |
| MILLENNIUM MANAGEMENT LLC | LAB Standard Biotools Inc. | 13G | 5.2% | Feb 16, 2024 | 2y |
| Slotting RemainCo Limited Partnership | FET Forum Energy Technologies, Inc. | 13G/A | 4.3% | Feb 16, 2024 | 2y |
| CQS (UK) LLP | URG Ur-Energy Inc | 13G | 5.27% | Feb 16, 2024 | 2y |
| Palantir Technologies Inc. | SRFM Surf Air Mobility Inc. | 13G | 7.1% | Feb 15, 2024 | 2y |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | KALV KalVista Pharmaceuticals, Inc. | 13G | 6.87% | Feb 15, 2024 | 2y |
| Ezra Friedberg | PTHS Pelthos Therapeutics Inc. | 13D | 9.5% | Feb 15, 2024 | 2y |
| Alpha 18 Inc. | AZTR Azitra, Inc. | 13G/A | 4.2% | Feb 14, 2024 | 2y |
| F. Hurst Lin (“Lin”) | AUGX Augmedix, Inc. Common Stock | 13D/A | 0.6% | Feb 14, 2024 | 2y |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | SOC Sable Offshore Corp. | 13G | 6.58% | Feb 14, 2024 | 2y |
| RS Fund LP | NURO NeuroMetrix, Inc. Common Stock | 13D | 14.4% | Feb 13, 2024 | 2y |
| Jonas Grossman | ATCH AtlasClear Holdings, Inc. | 13G | 9.99% | Feb 9, 2024 | 2y |
| Landy Toth | AMIX Autonomix Medical, Inc. | 13D | 10.8% | Jan 26, 2024 | 2y |
| Phoenix Financial Ltd. | CSTE Caesarstone Ltd. | 13G/A | 11.38% | Dec 31, 2023 | 2y |
| Mariano Gomide de Faria | VTEX Vtex | 13G/A | 31.7% | Dec 31, 2023 | 2y |
| Cowen Financial Products LLC | STOK Stoke Therapeutics, Inc. | 13G/A | 8.3% | Dec 29, 2023 | 2y |